Challenging the feasibility and clinical significance of current guidelines on lymph node examination in rectal cancer in the era of neoadjuvant therapy.
J. Clin. Oncol., Dec;29(34):4568-73 (2011)
Predicting survival after curative colectomy for cancer: individualizing colon cancer staging.
J. Clin. Oncol., Dec;29(36):4796-802 (2011)
Rate of residual disease after complete endoscopic resection of malignant colonic polyp.
Dis. Colon Rectum., Feb;55(2):122-7 (2012)
MET activation mediates resistance to lapatinib inhibition of HER2-amplified gastric cancer cells.
Mol. Cancer Ther., Mar;11(3):660-9 (2012)
Irreversible Electroporation Adjacent to the Rectum: Evaluation of Pathological Effects in a Pig Model.
Multivisceral resections for rectal cancer.
Br J Surg., Aug;99(8):1137-43 (2012)
Pulmonary recurrence predominates after combined modality therapy for rectal cancer: an original retrospective study.
Ann. Surg., Jul;256(1):111-6 (2012)
Nodal staging score: a tool to assess adequate staging of node-negative colon cancer.
J. Clin. Oncol., Dec;27(36):6166-71 (2009)
Randomized clinical trials in colon cancer.
Surg. Oncol. Clin. N. Am., Jan;19(1):183-204 (2010)
An update on laparoscopic resection for rectal cancer.
Cancer Control., Jan;17(1):16-24 (2010)
Randomized clinical trials in rectal and anal cancers.
Surg. Oncol. Clin. N. Am., Jan;19(1):205-23 (2010)
Quality of life and symptom control after stent placement or surgical palliation of malignant colorectal obstruction.
J. Am. Coll. Surg., Jan;210(1):45-53 (2010)
Clin Colon Rectal Surg., May;22(2):120-6 (2009)
Effects of obesity in rectal cancer surgery.
J. Am. Coll. Surg., Jul;211(1):55-60 (2010)
Prospective immunohistochemical analysis of primary colorectal cancers for loss of mismatch repair protein expression.
Clin Colorectal Cancer., Oct;9(4):255-9 (2010)
HGF rescues colorectal cancer cells from EGFR inhibition via MET activation.
Clin. Cancer Res., Feb;17(3):472-82 (2011)
A predictive model for lymph node yield in colon cancer resection specimens.
Ann. Surg., Feb;253(2):318-22 (2011)
Antitumor activity of SNX-2112, a synthetic heat shock protein-90 inhibitor, in MET-amplified tumor cells with or without resistance to selective MET Inhibition.
Clin. Cancer Res., Jan;17(1):122-33 (2011)
Immunohistochemical staining for DNA mismatch repair proteins in intestinal tract carcinoma: how reliable are biopsy samples?
Am. J. Surg. Pathol., Mar;35(3):447-54 (2011)
MET expression and amplification in patients with localized gastric cancer.
Cancer Epidemiol. Biomarkers Prev., May;20(5):1021-7 (2011)